Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Anti-infective antibodies: finding the path forward

Despite growing commercial interest in antimicrobial strategies that rely on antibodies, recent clinical trial failures suggest they are a work in progress.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: License to kill.

CNRI/Photo Researchers, Inc.


  1. Eash, S. Pharmacor, Infectious Disease, Study #2 2006 Decision Resources, Waltham, MA (2006) in press.

  2. Projan, S.J., Nesin, M. & Dunman, P.M. Curr. Opin. Pharmacol. 6, 473–479 (2006).

    Article  CAS  Google Scholar 

  3. Pirofski, L.A. & Casadevall, A. Curr. Opin. Microbiol. 9, 489–495 (2006).

    Article  CAS  Google Scholar 

  4. Casadevall, A. Clin. Infect. Dis. 42, 1414–1416 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Related links

Related links

Web links


Elusys Therapeutics

Nabi Biopharmaceuticals

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Baker, M. Anti-infective antibodies: finding the path forward. Nat Biotechnol 24, 1491–1493 (2006).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing